Can we change that legislatively? Or is the clock going to run out as you come back to work?
Well, you could, I think, help us if you could make a recommendation, again in the QFR window of this hearing.
I would encourage you to try to get an answer to us within the window that the chairman is going to provide for questions for the record.
I think these are good initiatives. They're really a top-down, not bottom-up approach.
I am supportive of doing something. I am actually not against this bill, but I think it's a piecemeal approach.
I think that regulatory reform and competition advocacy are very, very important.
I am also pleased to be in partnership with Representatives Johnson and Issa in a House companion to a bill.
Break them up. That is the remedy that I have advocated on some of the Big Tech companies.
We need to get that done immediately. That will add significant resources to the two agencies, plus the appropriations policy.
It is outrageous that we still have this practice going on where pharmaceuticals are paying their competitors to keep their products off the...
First, I would suggest negotiation of drug prices under Medicare, a bill that I lead with Representative Welch.
I want to thank Senators Grassley, Cornyn, and Klobuchar, and Blumenthal for their work on these important issues.
This legislation addresses product hopping, a particular abusive form of conduct used by drug manufacturers to extend their monopolies.
Today, pharmaceutical companies are confronting the American people with a terrible choice: Miss rent payments and skip meals to pay for the...
I look forward to joining Mr. Issa in reforming our Nation's patent laws.
to explicitly prohibit healthcare mergers that enable greater exploitation of existing market power and are likely to result in harm to cons...
You can't just do that and expect these healthcare pharma issues to be taken care of without funding those agencies.
I also have worked on that bill with Senator Grassley.
